These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 7624837)

  • 1. Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic pulmonary fibrosis.
    Kotani I; Sato A; Hayakawa H; Urano T; Takada Y; Takada A
    Thromb Res; 1995 Mar; 77(6):493-504. PubMed ID: 7624837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced tissue factor pathway activity and fibrin turnover in the alveolar compartment of patients with interstitial lung disease.
    Günther A; Mosavi P; Ruppert C; Heinemann S; Temmesfeld B; Velcovsky HG; Morr H; Grimminger F; Walmrath D; Seeger W
    Thromb Haemost; 2000 Jun; 83(6):853-60. PubMed ID: 10896238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Higher levels of urokinase plasminogen activator system components in the airways of chronic obstructive pulmonary disease patients].
    Xiao W; Tong WL; Ma DD
    Zhonghua Jie He He Hu Xi Za Zhi; 2006 Nov; 29(11):723-6. PubMed ID: 17327049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis.
    Senoo T; Hattori N; Tanimoto T; Furonaka M; Ishikawa N; Fujitaka K; Haruta Y; Murai H; Yokoyama A; Kohno N
    Thorax; 2010 Apr; 65(4):334-40. PubMed ID: 20388759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased mononuclear cell tissue factor and type-2 plasminogen activator inhibitor and reduced plasma fibrinolytic capacity in children with lymphoma.
    Semeraro N; Montemurro P; Giordano P; Santoro N; De Mattia D; Colucci M
    Thromb Haemost; 1994 Jul; 72(1):54-7. PubMed ID: 7974375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues.
    Umeda T; Eguchi Y; Okino K; Kodama M; Hattori T
    J Pathol; 1997 Dec; 183(4):388-97. PubMed ID: 9496254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pro- and antifibrinolytic properties of human pulmonary microvascular versus artery endothelial cells: impact of endotoxin and tumor necrosis factor-alpha.
    Muth H; Maus U; Wygrecka M; Lohmeyer J; Grimminger F; Seeger W; Günther A
    Crit Care Med; 2004 Jan; 32(1):217-26. PubMed ID: 14707582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasminogen activator inhibitor type 2: potential prognostic factor for endometrial carcinomas.
    Osmak M; Babić D; Abramić M; Milicić D; Vrhovec I; Skrk J
    Neoplasma; 2001; 48(6):462-7. PubMed ID: 11949838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of tissue plasminogen activator and plasminogen activator inhibitor-1 by transforming growth factor-beta in human retinal glial cells.
    Schacke W; Beck KF; Pfeilschifter J; Koch F; Hattenbach LO
    Invest Ophthalmol Vis Sci; 2002 Aug; 43(8):2799-805. PubMed ID: 12147618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salmeterol enhances pulmonary fibrinolysis in healthy volunteers.
    Maris NA; de Vos AF; Bresser P; van der Zee JS; Jansen HM; Levi M; van der Poll T
    Crit Care Med; 2007 Jan; 35(1):57-63. PubMed ID: 17080003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.
    Leonardi A; Brun P; Sartori MT; Cortivo R; Dedominicis C; Saggiorato G; Abatangelo G; Secchi AG
    Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1364-70. PubMed ID: 15790903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
    Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
    Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis.
    Kim SJ; Shiba E; Kobayashi T; Yayoi E; Furukawa J; Takatsuka Y; Shin E; Koyama H; Inaji H; Takai S
    Clin Cancer Res; 1998 Jan; 4(1):177-82. PubMed ID: 9516968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptional regulation of tissue- and urokinase-type plasminogen activator genes by thrombin in human fetal lung fibroblasts.
    Hayakawa Y; Tazawa S; Ishikawa T; Niiya K; Sakuragawa N
    Thromb Haemost; 1995 Aug; 74(2):704-10. PubMed ID: 8585010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma.
    Hofmann R; Lehmer A; Buresch M; Hartung R; Ulm K
    Cancer; 1996 Aug; 78(3):487-92. PubMed ID: 8697395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relevance of tissue factor and tissue factor pathway inhibitor for hypercoagulable state in the lungs of patients with idiopathic pulmonary fibrosis.
    Fujii M; Hayakawa H; Urano T; Sato A; Chida K; Nakamura H; Takada A
    Thromb Res; 2000 Jul; 99(2):111-7. PubMed ID: 10946084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue plasminogen activator (t-PA) and placental plasminogen activator inhibitor (PAI-2) in gingival crevicular fluid from patients with Papillon-Lefèvre syndrome.
    Ullbro C; Kinnby B; Lindberg P; Matsson L
    J Clin Periodontol; 2004 Sep; 31(9):708-12. PubMed ID: 15312091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma.
    Stabuc B; Markovic J; Bartenjev I; Vrhovec I; Medved U; Kocijancic B
    Oncol Rep; 2003; 10(3):635-9. PubMed ID: 12684636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cultured human mesangial cells produce both type 1 and type 2 plasminogen activator inhibitors.
    Colucci M; Gesualdo L; Montemurro P; Cavallo LG; Conese M; Mascolo E; Ranieri E; Di Paolo S; Schena FP; Semeraro N
    Thromb Haemost; 1995 Dec; 74(6):1516-20. PubMed ID: 8772230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular degradation of free and inhibitor-bound tissue-type plasminogen activator--requirement for a co-receptor?
    Camani C; Gavin O; Kruithof EK
    Thromb Haemost; 2000 Feb; 83(2):290-6. PubMed ID: 10739388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.